Tremelimumab side effects

Tremelimumab (tremelimumab) combined with durvalumab is suitable for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC), and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities.

Serious adverse reactions occurred in 41% of patients with hepatocellular carcinoma who received temsitumumab plus durvalumab. Serious adverse reactions occurring in more than 1% of patients included bleeding (6%), diarrhea (4%), sepsis (2.1%), pneumonia (2.1%), rash (1.5%), vomiting (1.3%), acute kidney injury (1.3%), and anemia (1.3%). Fatal adverse reactions occurred in 8%, including death (1%), intracranial hemorrhage (0.5%), cardiac arrest (0.5%), pneumonia (0.5%), liver failure (0.5%), and immune-mediated hepatitis (0.5%). The most common adverse reactions (occurring in ≥20% of patients) were rash, diarrhea, fatigue, pruritus, musculoskeletal pain, and abdominal pain. Fourteen percent of patients permanently discontinued treatment due to adverse reactions, including bleeding (1.8%), diarrhea (1.5%), AST elevation (1%), and hepatitis (1%). Thirty-five percent of patients experienced dose interruptions or treatment delays due to adverse reactions.

Non-small cell lung cancer patients44% of non-small cell lung cancer patients who received temsitumumab combined with durvalumab and platinum-based chemotherapy experienced serious adverse reactions. The most common serious adverse reactions reported in at least 2% of patients were pneumonitis (11%), anemia (5%), diarrhea (2.4%), thrombocytopenia (2.4%), pyrexia (2.4%), and febrile neutropenia (2.1%), with a total of fatal adverse reactions occurring in 4.2% , including hepatitis, nephritis, myocarditis, pancreatitis, death (2 cases), sepsis (2 cases), pneumonia (2 cases), acute kidney injury (2 cases), febrile neutropenia (1 case), chronic obstructive pulmonary disease (1 case), dyspnea (1 case), sudden death (1 case), and ischemic stroke (1 case). Seventeen percent of patients permanently discontinued temsitumumab or durvalumab due to adverse reactions (pneumonitis), and 41% of patients had their temsitumumab or durvalumab dose interrupted or delayed due to adverse reactions.

Tesetumumab is an emerging cancer immunotherapy drug that has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab’s original drug has been on the market overseas for a short time, and the price is not yet clear. There is currently no known generic version of temsitumumab that has been produced and launched. For specific prices and drug details, please consult Yaode’s medical consultant.